SphynKx Therapeutics LLC is a privately held biotechnology company based in Charlottesville, Va., focused on discovering, developing and commercializing novel sphingosine kinase (SphK) inhibitors for the treatment of fibrosis.
Nearly 45 percent of deaths in the U.S. can be attributed to disorders with a significant fibrotic component, yet there are no FDA-approved therapies to treat this pathology.
The SphynKx Therapeutics team possesses world-class expertise in the field of SphK chemical biology, and the company’s drug discovery platform has generated a portfolio of potent and selective sphingosine kinase inhibitors with promising pre-clinical activity. The company’s pipeline includes both SphK1 and SphK2-selective inhibitors.U.Va. Founders: Kevin R. Lynch, Timothy L. Macdonald